Employers Limit GLP-1 Access, Andel and Novo Suggest Alternatives | Retatrutide News

Employers are limiting access to GLP-1 drugs, prompting Andel and Novo Nordisk to propose alternatives. This situation highlights the challenges in main...
Market News · November 2, 2026